Accéder au contenu
Merck
Toutes les photos(1)

Key Documents

View All Documentation

Y0001586

Atomoxetine hydrochloride

European Pharmacopoeia (EP) Reference Standard

Synonyme(s) :

(R)-Tomoxetine hydrochloride, (R)-N-Methyl-γ-(2-methyl­phenoxy)benzenepropanamine hydrochloride, Atomoxetine hydrochloride

Se connecterpour consulter vos tarifs contractuels et ceux de votre entreprise/organisme
Toutes les photos(1)

About This Item

Formule empirique (notation de Hill):
C17H21NO · HCl
Numéro CAS:
82248-59-7
Poids moléculaire :
291.82
Numéro MDL:
MFCD06410992
Code UNSPSC :
41116107
ID de substance PubChem :
329831496
Nomenclature NACRES :
NA.24

Qualité

pharmaceutical primary standard

Famille d'API

atomoxetine

Fabricant/nom de marque

EDQM

Application(s)

pharmaceutical (small molecule)

Format

neat

Température de stockage

2-8°C

Chaîne SMILES 

CNCC[C@@H](OC1=CC=CC=C1C)C2=CC=CC=C2.[H]Cl

InChI

1S/C17H21NO.ClH/c1-14-8-6-7-11-16(14)19-17(12-13-18-2)15-9-4-3-5-10-15;/h3-11,17-18H,12-13H2,1-2H3;1H/t17-;/m1./s1

Clé InChI

LUCXVPAZUDVVBT-UNTBIKODSA-N

Informations sur le gène

human ... SLC6A2(6530)

Vous recherchez des produits similaires ? Visite Guide de comparaison des produits

Description générale

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

Application

Atomoxetine hydrochloride EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

Actions biochimiques/physiologiques

Norepinephrine uptake blocker.

Conditionnement

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

Autres remarques

Sales restrictions may apply.

Produit(s) apparenté(s)

Réf. du produit
Description
Tarif

Y0001589

Atomoxetine impurity D, European Pharmacopoeia (EP) Reference Standard

Y0001588

Atomoxetine impurity B, European Pharmacopoeia (EP) Reference Standard

Y0001587

Atomoxetine for impurity A identification, European Pharmacopoeia (EP) Reference Standard

1044469

Atomoxetine hydrochloride, United States Pharmacopeia (USP) Reference Standard

1044913

Atomoxetine S-isomer, United States Pharmacopeia (USP) Reference Standard

1044488

Atomoxetine Related Compound B, United States Pharmacopeia (USP) Reference Standard

1044491

Atomoxetine Related Compound C, United States Pharmacopeia (USP) Reference Standard

1044470

Atomoxetine Related Compound A, United States Pharmacopeia (USP) Reference Standard

PHR1679

Atomoxetine Hydrochloride, Pharmaceutical Secondary Standard; Certified Reference Material

PHR2840

Atomoxetine Related Compound A, Pharmaceutical Secondary Standard; Certified Reference Material

Code de la classe de stockage

11 - Combustible Solids

Classe de danger pour l'eau (WGK)

WGK 3

Point d'éclair (°F)

Not applicable

Point d'éclair (°C)

Not applicable

Faites votre choix parmi les versions les plus récentes :

Certificats d'analyse (COA)

Lot/Batch Number

Désolés, nous n'avons pas de COA pour ce produit disponible en ligne pour le moment.

Si vous avez besoin d'assistance, veuillez contacter Service Clients

Déjà en possession de ce produit ?

Retrouvez la documentation relative aux produits que vous avez récemment achetés dans la Bibliothèque de documents.

Consulter la Bibliothèque de documents

Les clients ont également consulté

Slide 1 of 1

1 of 1

Fluoxétine hydrochloride solid

Sigma-Aldrich

F132

Fluoxétine hydrochloride

METHOD DEVELOPMENT AND VALIDATION FOR THE ESTIMATION OF ATOMOXETINE HYDROCHLORIDE IN BULK AND CAPSULE DOSAGE FORM BY RP-HPLC.
Swathi G, et al.
World Journal of Pharmacy and Pharmaceutical Sciences (2015)
Atomoxetine hydrochloride in the treatment of children and adolescents with attention-deficit/hyperactivity disorder and comorbid oppositional defiant disorder: A placebo-controlled Italian study.
Dell'Agnello G, et al.
European Neuropsychopharmacology, 19(11), 822-834 (2009)
Irene Joy I Dela Peña et al.
Progress in neuro-psychopharmacology & biological psychiatry, 88, 311-319 (2018-08-21)
Attention-deficit/hyperactivity disorder (ADHD) is a heterogeneous neurodevelopmental disorder characterized by varying levels of hyperactivity, inattention, and impulsivity. Patients with ADHD are often classified as (1) predominantly hyperactive-impulsive, (2) predominantly inattentive, and (3) combined type. There is a growing interest in
Chloe J Jordan et al.
Drug and alcohol dependence, 140, 25-32 (2014-05-09)
Attention-deficit/hyperactivity disorder (ADHD) is often comorbid with cocaine abuse. Controversy exists regarding long-term consequences of ADHD medications on cocaine abuse liability. Whereas childhood methylphenidate treatment may be preventative, methylphenidate in teens appears to further increase later cocaine abuse risk. In
Joshua Caballero et al.
Clinical therapeutics, 25(12), 3065-3083 (2004-01-30)
Attention-deficit/hyperactivity disorder (ADHD) occurs in approximately 3% to 10% of the pediatric population. Most of the drugs typically used to treat ADHD are stimulants, which, because of their addictive properties and potential for abuse, are controlled substances. Although these drugs
Afficher tous les articles scientifiques apparentés

Notre équipe de scientifiques dispose d'une expérience dans tous les secteurs de la recherche, notamment en sciences de la vie, science des matériaux, synthèse chimique, chromatographie, analyse et dans de nombreux autres domaines..

Contacter notre Service technique